Literature DB >> 1537166

Pudendal nerve palsy following fracture table traction.

M P France1, B F Aurori.   

Abstract

In separate retrospective and prospective studies at the same Level 1 trauma center, pudendal nerve palsy complicating fracture table cases was analyzed. Incidence was established and pertinent variables categorized and compared. From January 1986 through October 1988, four of 216 fracture table patients (1.9%) were diagnosed with a postoperative pudendal nerve palsy. A subsequent three-month prospective study, ensuring use of preventive measures and incorporating active postoperative screening, resulted in only one of 36 patients (2.8%) developing this complication after fracture table traction. Symptoms associated with this palsy, including genitoperineal hypoesthesia, erectile dysfunction, or both, occurred within the first two postoperative days and resolved spontaneously by six months. No association of variables had any statistical significance. The pathoanatomy of this complication and preventive guidelines are reviewed.

Entities:  

Mesh:

Year:  1992        PMID: 1537166

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Scrotum wound caused by orthopaedic traction table in the surgery of femoral neck fracture.

Authors:  Abbas Abdoli Tafti; Sanaz Sajadi; Hossein Rafiei
Journal:  Int Wound J       Date:  2013-04-10       Impact factor: 3.315

Review 2.  Pudendal nerve injury is a relatively common but transient complication of hip arthroscopy.

Authors:  Anthony Habib; Chloe E Haldane; Seper Ekhtiari; Darren de Sa; Nicole Simunovic; Etienne L Belzile; Olufemi R Ayeni
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-11-08       Impact factor: 4.342

3.  Traction table versus double reverse traction repositor in the treatment of femoral shaft fractures.

Authors:  Ruipeng Zhang; Yingchao Yin; Shilun Li; Lin Jin; Zhiyong Hou; Yingze Zhang
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.